U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923734) titled 'Study of Electrocardiogram (ECG) Safety of Sezaby in Neonatal Seizures' on Oct. 13.
Brief Summary: This Phase 4, multicenter, single-arm, open-label study evaluates the effect of intravenous Sezaby (phenobarbital sodium) on electrocardiographic safety, including the QT interval, in neonates with seizures.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Neonatal Seizure
Intervention:
DRUG: Sezaby
Sezaby (phenobarbital sodium for injection) is administered as intravenous loading and maintenance doses over a treatment period of up to 5 days for the treatment of neonatal seizures.
Recruitment Status: NOT_YET_RE...